CORRECTED-Novartis lung drug not inferior to GSK's Seretide, study shows
(Removes paragraph on QVA149, which refers to Ultibro Breezhaler not Onbrez Breezhaler)
ZURICH, April 25 (Reuters) - Patients taking Novartis' inhaled medicine Onbrez Breezhaler for chronic lung disease had benefits similar to those taking GlaxoSmithKline's Seretide, the Swiss drugmaker said on Friday, citing a late stage study.
The Phase IV study in patients with moderate chronic obstructive pulmonary disease (COPD) found Novartis' once-daily drug showed similar benefits in reducing shortness of breath as GSK's Seretide, which must be taken twice daily.
Around 210 million people worldwide suffer from COPD, a disease that causes breathing trouble and chronic coughing, and is sometimes fatal. (Reporting by Caroline Copley; Editing by Edwina Gibbs and Jane Baird)
- Gaza gunmen execute 'collaborators'; mortar kills Israeli boy |
- Ferguson march muted, police officer disciplined over video |
- U.S. says Russia must pull convoy from Ukraine or face more sanctions |
- U.S. hostage rescuers dropped from night sky: Syria activist
- U.S. protests intercept of Navy jet by Chinese warplane